Testing the Effect of a Warning About New Drugs

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00950131

Enrollment

2944

Registered

2009-07-31

Start date

2009-08-31

Completion date

2009-09-30

Last updated

2010-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Risk Communication

Brief summary

The purpose of this study is to test whether a new drug warning decreases enthusiasm for new drugs.

Interventions

OTHERPresentation of information about drug approval and level of warning

Presentation of information about date of drug approval with no new drug warning, a non-directive drug box warning or a directive drug box warning

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Participants will be randomly selected from a research panel of more than 60,000 U.S. households (Knowledge Networks).

Design outcomes

Primary

Measure	Time frame
Hypothetical choice of old (vs. newer) drug	0 weeks (assessed during intervention)

Secondary

Measure	Time frame
Comprehension of the drug warning and drug information	0 weeks (assessed during intervention)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 28, 2026